以嶺藥業(002603.SZ)：擬增加公司經營範圍
格隆匯 12 月 7日丨以嶺藥業(002603.SZ)公佈，公司第七屆董事會第十次會議決議，審議通過了《關於增加公司經營範圍的議案》。
原經營範圍為：硬膠囊劑、片劑、顆粒劑、合劑、小容量注射劑、中藥配方顆粒、塑料製品的生產；保健食品的生產、銷售(許可生產品種以食品生產許可品種明細表核准的為準)；飲料(固體飲料類、其他飲料類)的生產、銷售(許可生產食品品種以食品生產許可證副頁核准的為準)；方便食品的生產、銷售(許可生產食品品種以食品生產許可證副頁核准的為準)；中藥提取物的生產；自營和代理各類商品和技術的進出口，但國家限定公司經營和禁止進出口的商品和技術除外；自有房屋租賃；機械設備租賃；傢俱、家用電器租賃；農產品收購(不含糧食)；糖果製品的生產、銷售(許可生產食品品種以食品生產許可證副頁核準的為準)；企業管理諮詢服務；健康管理諮詢服務(診療、醫療、心理諮詢除外)。(以下限分支機構經營)；中成藥、醫藥保健品、傳統醫療器械、西藥、生物製品、衞生輔料的研究、開發；技術諮詢、服務、轉讓；(依法須經批准的項目，經相關部門批准後方可開展經營活動)。
擬變更為：硬膠囊劑、片劑、顆粒劑、合劑、小容量注射劑、中藥配方顆粒、塑料製品的生產；保健食品的生產、銷售(許可生產品種以食品生產許可品種明細表核准的為準)；飲料(固體飲料類、其他飲料類)的生產、銷售(許可生產食品品種以食品生產許可證副頁核准的為準)；方便食品的生產、銷售(許可生產食品品種以食品生產許可證副頁核准的為準)；中藥提取物的生產；自營和代理各類商品和技術的進出口，但國家限定公司經營和禁止進出口的商品和技術除外；自有房屋租賃；機械設備租賃；傢俱、家用電器租賃；農產品收購(不含糧食)；糖果製品的生產、銷售(許可生產食品品種以食品生產許可證副頁核准的為準)；企業管理諮詢服務；健康管理諮詢服務(診療、醫療、心理諮詢除外)。(以下限分支機構經營)；中成藥、醫藥保健品、傳統醫療器械、西藥、生物制品、衞生輔料的研究、開發；技術諮詢、服務、轉讓；普通貨運，貨物專用運輸(冷藏保鮮)；(依法須經批准的項目，經相關部門批准後方可開展經營活動)。
(注：經營範圍內容最終以工商登記部門核准為準)
該議案需提請公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
